Recombinant Human CD209 (N-Fc)

Description

EnkiLife provides the Recombinant Human CD209 (N-Fc) protein,aslo know as CD209 molecule,CD209,CDSIGNHIV gpl20-binding protein,CLEC4L,DCSIGN,DC-SIGN,DC-SIGN1, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human CD209 Antigen is produced by our Mammalian expression system and the target gene encoding Gln59-Ala404 is expressed with a human IgG1 Fc tag at the N-terminus.Accession:Q9NNX6. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:65.3 KDa. Background:CD209 is also known as CLEC4L, DC-SIGN and CD209 antigen, is a type II transmembrane protein on DCs with a C-type lectin extracellular domain, is capable of binding ICAM-3 on resting T cells in the secondary lymphoid organs, providing the initial contact between these cells during the establishment of cell-mediated immunity. The DC-SIGN/CD209 lectin domain binds mannose oligosaccharides on pathogens including HIV as well as self glycoproteins including ICAMs (2, 4). DC-SIGN/CD209 binds to butyrophilin 2A1 and this interaction can be blocked by HIV pp120. DC-SIGN/CD209 is expressed on dendritic cells (DC) and inflammatory macrophages and contributes to antigen presentation. It is not only a pattern recognition receptor but implicated in immunoregulation of DCs. It has important role in mediating DC adhesion, migration, inflammation, activating primary T cell, triggering immune response and participating in immune escape of pathogens and tumors.